{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T18:56:06Z","timestamp":1792608966759,"version":"4.5.0"},"reference-count":61,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ajkd.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1053\/j.ajkd.2018.03.025","type":"journal-article","created":{"date-parts":[[2018,6,14]],"date-time":"2018-06-14T02:14:05Z","timestamp":1528942445000},"page":"519-528","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":119,"title":["GDF-15, Galectin 3, Soluble ST2, and Risk of Mortality and Cardiovascular Events in CKD"],"prefix":"10.1053","volume":"72","author":[{"given":"Courtney","family":"Tuegel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronit","family":"Katz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariam","family":"Alam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeenat","family":"Bhat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Bellovich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"de Boer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Brosius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Crystal","family":"Gadegbeku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debbie","family":"Gipson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Hawkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Himmelfarb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjun","family":"Ju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan","family":"Kestenbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Kretzler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cassianne","family":"Robinson-Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Steigerwalt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nisha","family":"Bansal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"suppl 1","key":"10.1053\/j.ajkd.2018.03.025_bib1","doi-asserted-by":"crossref","first-page":"A7","DOI":"10.1053\/j.ajkd.2016.12.004","article-title":"US Renal Data System 2016 Annual Data Report: epidemiology of kidney disease in the United States","volume":"69","author":"Saran","year":"2017","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ajkd.2018.03.025_bib2","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.2215\/CJN.09990915","article-title":"Predictors and outcomes of health-related quality of life in adults with CKD","volume":"11","author":"Porter","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2018.03.025_bib3","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1681\/ASN.2014060614","article-title":"Rehospitalizations and emergency department visits after hospital discharge in patients receiving maintenance hemodialysis","volume":"26","author":"Harel","year":"2015","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2018.03.025_bib4","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1056\/NEJMoa041031","article-title":"Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization","volume":"351","author":"Go","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.ajkd.2018.03.025_bib5","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/ejhf.273","article-title":"State of the art: newer biomarkers in heart failure","volume":"17","author":"de Boer","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"10.1053\/j.ajkd.2018.03.025_bib6","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.cytogfr.2013.05.003","article-title":"The multiple facets of the TGF-beta family cytokine growth\/differentiation factor-15\/macrophage inhibitory cytokine-1","volume":"24","author":"Unsicker","year":"2013","journal-title":"Cytokine Growth Factor Rev"},{"issue":"7","key":"10.1053\/j.ajkd.2018.03.025_bib7","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1681\/ASN.2016080919","article-title":"Growth differentiation factor-15 and risk of CKD progression","volume":"28","author":"Nair","year":"2017","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2018.03.025_bib8","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1161\/01.RES.0000202805.73038.48","article-title":"The transforming growth factor-beta superfamily member growth-differentiation factor-15 protects the heart from ischemia\/reperfusion injury","volume":"98","author":"Kempf","year":"2006","journal-title":"Circ Res"},{"key":"10.1053\/j.ajkd.2018.03.025_bib9","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1161\/CIRCULATIONAHA.112.129437","article-title":"Prognostic utility of novel biomarkers of cardiovascular stress: the Framingham Heart Study","volume":"126","author":"Wang","year":"2012","journal-title":"Circulation"},{"key":"10.1053\/j.ajkd.2018.03.025_bib10","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1373\/clinchem.2011.171926","article-title":"Association of growth differentiation factor-15 with coronary atherosclerosis and mortality in a young, multiethnic population: observations from the Dallas Heart Study","volume":"58","author":"Rohatgi","year":"2012","journal-title":"Clin Chem"},{"key":"10.1053\/j.ajkd.2018.03.025_bib11","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1373\/clinchem.2006.076828","article-title":"Circulating concentrations of growth-differentiation factor 15 in apparently healthy elderly individuals and patients with chronic heart failure as assessed by a new immunoradiometric sandwich assay","volume":"53","author":"Kempf","year":"2007","journal-title":"Clin Chem"},{"key":"10.1053\/j.ajkd.2018.03.025_bib12","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1161\/ATVBAHA.110.213512","article-title":"Growth differentiation factor-15 and risk of recurrent events in patients stabilized after acute coronary syndrome: observations from PROVE IT-TIMI 22","volume":"31","author":"Bonaca","year":"2011","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1053\/j.ajkd.2018.03.025_bib13","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.jacc.2007.04.091","article-title":"Prognostic utility of growth differentiation factor-15 in patients with chronic heart failure","volume":"50","author":"Kempf","year":"2007","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1053\/j.ajkd.2018.03.025_bib14","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1161\/CIRCULATIONAHA.109.928846","article-title":"Serial measurement of growth-differentiation factor-15 in heart failure: relation to disease severity and prognosis in the Valsartan Heart Failure Trial","volume":"122","author":"Anand","year":"2010","journal-title":"Circulation"},{"key":"10.1053\/j.ajkd.2018.03.025_bib15","doi-asserted-by":"crossref","first-page":"e000399","DOI":"10.1161\/JAHA.113.000399","article-title":"Association of novel biomarkers of cardiovascular stress with left ventricular hypertrophy and dysfunction: implications for screening","volume":"2","author":"Xanthakis","year":"2013","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1053\/j.ajkd.2018.03.025_bib16","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1093\/eurheartj\/ehp261","article-title":"Growth-differentiation factor-15 is an independent marker of cardiovascular dysfunction and disease in the elderly: results from the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) Study","volume":"30","author":"Lind","year":"2009","journal-title":"Eur Heart J"},{"key":"10.1053\/j.ajkd.2018.03.025_bib17","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1093\/eurheartj\/ehm465","article-title":"Growth-differentiation factor-15 improves risk stratification in ST-segment elevation myocardial infarction","volume":"28","author":"Kempf","year":"2007","journal-title":"Eur Heart J"},{"key":"10.1053\/j.ajkd.2018.03.025_bib18","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s11897-012-0113-9","article-title":"Growth differentiation factor 15 in heart failure: an update","volume":"9","author":"Wollert","year":"2012","journal-title":"Curr Heart Fail Rep"},{"key":"10.1053\/j.ajkd.2018.03.025_bib19","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1161\/CIRCULATIONAHA.107.697714","article-title":"Growth differentiation factor 15 for risk stratification and selection of an invasive treatment strategy in non ST-elevation acute coronary syndrome","volume":"116","author":"Wollert","year":"2007","journal-title":"Circulation"},{"key":"10.1053\/j.ajkd.2018.03.025_bib20","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1161\/CIRCULATIONAHA.106.650846","article-title":"Prognostic value of growth-differentiation factor-15 in patients with non-ST-elevation acute coronary syndrome","volume":"115","author":"Wollert","year":"2007","journal-title":"Circulation"},{"key":"10.1053\/j.ajkd.2018.03.025_bib21","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1373\/clinchem.2016.255174","article-title":"Growth differentiation factor 15 as a biomarker in cardiovascular disease","volume":"63","author":"Wollert","year":"2017","journal-title":"Clin Chem"},{"key":"10.1053\/j.ajkd.2018.03.025_bib22","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1161\/ATVBAHA.112.300569","article-title":"Galectin-3 mediates aldosterone-induced vascular fibrosis","volume":"33","author":"Calvier","year":"2013","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1053\/j.ajkd.2018.03.025_bib23","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1161\/HYPERTENSIONAHA.115.06161","article-title":"Inhibition of galectin-3 pathway prevents isoproterenol-induced left ventricular dysfunction and fibrosis in mice","volume":"67","author":"Vergaro","year":"2016","journal-title":"Hypertension"},{"key":"10.1053\/j.ajkd.2018.03.025_bib24","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.atherosclerosis.2017.03.031","article-title":"Galectin-3 binding protein, coronary artery disease and cardiovascular mortality: insights from the LURIC study","volume":"260","author":"Gleissner","year":"2017","journal-title":"Atherosclerosis"},{"key":"10.1053\/j.ajkd.2018.03.025_bib25","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1080\/1354750X.2017.1319421","article-title":"The GALA study: relationship between galectin-3 serum levels and short- and long-term outcomes of patients with acute heart failure","volume":"22","author":"Mir\u00f3","year":"2017","journal-title":"Biomarkers"},{"key":"10.1053\/j.ajkd.2018.03.025_bib26","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1681\/ASN.2014010093","article-title":"Galectin-3, renal function, and clinical outcomes: results from the LURIC and 4D studies","volume":"26","author":"Drechsler","year":"2015","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2018.03.025_bib27","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.jacc.2013.07.087","article-title":"Head-to-head comparison of 2 myocardial fibrosis biomarkers for long-term heart failure risk stratification: ST2 versus galectin-3","volume":"63","author":"Bayes-Genis","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1053\/j.ajkd.2018.03.025_bib28","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1056\/NEJM197112232852601","article-title":"The natural history of congestive heart failure: the Framingham study","volume":"285","author":"McKee","year":"1971","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.ajkd.2018.03.025_bib29","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ahj.2006.10.012","article-title":"The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Heart Failure Validation Study: diagnosis and prognosis","volume":"153","author":"Einhorn","year":"2007","journal-title":"Am Heart J"},{"key":"10.1053\/j.ajkd.2018.03.025_bib30","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.1161\/CIRCULATIONAHA.107.187397","article-title":"Universal definition of myocardial infarction","volume":"116","author":"Thygesen","year":"2007","journal-title":"Circulation"},{"key":"10.1053\/j.ajkd.2018.03.025_bib31","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1161\/01.STR.30.4.736","article-title":"Stroke incidence and survival among middle-aged adults: 9-year follow-up of the Atherosclerosis Risk in Communities (ARIC) cohort","volume":"30","author":"Rosamond","year":"1999","journal-title":"Stroke"},{"key":"10.1053\/j.ajkd.2018.03.025_bib32","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1373\/clinchem.2016.260570","article-title":"Growth differentiation factor 15 predicts all-cause morbidity and mortality in stable coronary heart disease","volume":"63","author":"Hagstrom","year":"2017","journal-title":"Clin Chem"},{"key":"10.1053\/j.ajkd.2018.03.025_bib33","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1182\/blood-2016-01-696617","article-title":"GDF-15 inhibits integrin activation and mouse neutrophil recruitment through the ALK-5\/TGF-betaRII heterodimer","volume":"128","author":"Artz","year":"2016","journal-title":"Blood"},{"key":"10.1053\/j.ajkd.2018.03.025_bib34","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/nm.2354","article-title":"GDF-15 is an inhibitor\u00a0of leukocyte integrin activation required for survival\u00a0after myocardial infarction in mice","volume":"17","author":"Kempf","year":"2011","journal-title":"Nat Med"},{"key":"10.1053\/j.ajkd.2018.03.025_bib35","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1038\/nm.4394","article-title":"GFRAL is the receptor for GDF15 and is required for the anti-obesity effects of the ligand","volume":"23","author":"Yang","year":"2017","journal-title":"Nat Med"},{"key":"10.1053\/j.ajkd.2018.03.025_bib36","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1038\/nm.4393","article-title":"The metabolic effects of GDF15 are mediated by the orphan receptor GFRAL","volume":"23","author":"Emmerson","year":"2017","journal-title":"Nat Med"},{"key":"10.1053\/j.ajkd.2018.03.025_bib37","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.ahj.2013.12.031","article-title":"Galectin-3 is independently associated with cardiovascular mortality in community-dwelling older adults without known cardiovascular disease: the Rancho Bernardo Study","volume":"167","author":"Daniels","year":"2014","journal-title":"Am Heart J"},{"key":"10.1053\/j.ajkd.2018.03.025_bib38","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.amjcard.2016.09.019","article-title":"Meta-analysis of the usefulness of plasma galectin-3 to predict the risk of mortality in patients with heart failure and in the general population","volume":"119","author":"Imran","year":"2017","journal-title":"Am J Cardiol"},{"key":"10.1053\/j.ajkd.2018.03.025_bib39","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1161\/ATVBAHA.114.304964","article-title":"Galectin-3 predicts long-term cardiovascular death in high-risk patients with coronary artery disease","volume":"35","author":"Maiolino","year":"2015","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1053\/j.ajkd.2018.03.025_bib40","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1093\/eurjhf\/hfp097","article-title":"Galectin-3: a novel mediator of heart failure development and progression","volume":"11","author":"de Boer","year":"2009","journal-title":"Eur J Heart Fail"},{"key":"10.1053\/j.ajkd.2018.03.025_bib41","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.jacc.2012.04.053","article-title":"Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community","volume":"60","author":"Ho","year":"2012","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1053\/j.ajkd.2018.03.025_bib42","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.jacc.2006.03.061","article-title":"Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure","volume":"48","author":"van Kimmenade","year":"2006","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1053\/j.ajkd.2018.03.025_bib43","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3109\/07853890.2010.538080","article-title":"Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction","volume":"43","author":"de Boer","year":"2011","journal-title":"Ann Med"},{"key":"10.1053\/j.ajkd.2018.03.025_bib44","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1159\/000446376","article-title":"Galectin-3 in renal pathology: more than just an innocent bystander","volume":"43","author":"Desmedt","year":"2016","journal-title":"Am J Nephrol"},{"key":"10.1053\/j.ajkd.2018.03.025_bib45","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1093\/glycob\/cwt006","article-title":"Inhibition of galectin-3 reduces atherosclerosis in apolipoprotein E-deficient mice","volume":"23","author":"MacKinnon","year":"2013","journal-title":"Glycobiology"},{"key":"10.1053\/j.ajkd.2018.03.025_bib46","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.kint.2017.06.028","article-title":"Plasma galectin-3 levels are associated with the risk of incident chronic kidney disease","volume":"93","author":"Rebholz","year":"2018","journal-title":"Kidney Int"},{"issue":"5","key":"10.1053\/j.ajkd.2018.03.025_bib47","doi-asserted-by":"crossref","first-page":"e000760","DOI":"10.1161\/JAHA.112.000760","article-title":"Relationship of plasma galectin-3 to renal function in patients with heart failure: effects of clinical status, pathophysiology of heart failure, and presence or absence of heart failure","volume":"1","author":"Gopal","year":"2012","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1053\/j.ajkd.2018.03.025_bib48","doi-asserted-by":"crossref","first-page":"e000962","DOI":"10.1161\/JAHA.114.000962","article-title":"Renal handling of galectin-3 in the general population, chronic heart failure, and hemodialysis","volume":"3","author":"Meijers","year":"2014","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1053\/j.ajkd.2018.03.025_bib49","first-page":"31","article-title":"Diagnostic and prognostic value of galectin-3, serum creatinine, and cystatin C in chronic kidney diseases","volume":"5","author":"Ji","year":"2017","journal-title":"J\u00a0Clin Lab Anal"},{"key":"10.1053\/j.ajkd.2018.03.025_bib50","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ijcard.2014.09.011","article-title":"Renal function largely influences galectin-3 prognostic value in heart failure","volume":"177","author":"Zamora","year":"2014","journal-title":"Int J Cardiol"},{"key":"10.1053\/j.ajkd.2018.03.025_bib51","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.ahj.2010.06.033","article-title":"Association of ST2 levels with cardiac structure and function and mortality in outpatients","volume":"160","author":"Daniels","year":"2010","journal-title":"Am Heart J"},{"key":"10.1053\/j.ajkd.2018.03.025_bib52","doi-asserted-by":"crossref","first-page":"26b","DOI":"10.1016\/j.amjcard.2015.01.037","article-title":"ST2 and prognosis in acutely decompensated heart failure: the International ST2 Consensus Panel","volume":"115","author":"Januzzi","year":"2015","journal-title":"Am J Cardiol"},{"key":"10.1053\/j.ajkd.2018.03.025_bib53","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1515\/cclm-2015-0074","article-title":"Clinical relevance of sST2 in cardiac diseases","volume":"54","author":"Pascual-Figal","year":"2016","journal-title":"Clin Chem Lab Med"},{"key":"10.1053\/j.ajkd.2018.03.025_bib54","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s12265-013-9459-y","article-title":"ST2 as a cardiovascular risk biomarker: from the bench to the bedside","volume":"6","author":"Januzzi","year":"2013","journal-title":"J\u00a0Cardiovasc Transl Res"},{"key":"10.1053\/j.ajkd.2018.03.025_bib55","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1161\/CIRCHEARTFAILURE.110.958223","article-title":"High-sensitivity ST2 for prediction of adverse outcomes in chronic heart failure","volume":"4","author":"Ky","year":"2011","journal-title":"Circ Heart Fail"},{"key":"10.1053\/j.ajkd.2018.03.025_bib56","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.cyto.2012.06.002","article-title":"Interleukin-21\u2013a biomarker of importance in predicting myocardial function following acute infarction?","volume":"60","author":"Weir","year":"2012","journal-title":"Cytokine"},{"key":"10.1053\/j.ajkd.2018.03.025_bib57","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.jacc.2009.08.047","article-title":"Serum soluble ST2: a potential novel mediator in left ventricular and infarct remodeling after acute myocardial infarction","volume":"55","author":"Weir","year":"2010","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1053\/j.ajkd.2018.03.025_bib58","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/ejhf.443","article-title":"Optimizing clinical use of biomarkers in high-risk acute heart failure patients","volume":"18","author":"Demissei","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"10.1053\/j.ajkd.2018.03.025_bib59","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.cardfail.2013.09.005","article-title":"Soluble ST2 serum concentration and renal function in heart failure","volume":"19","author":"Bayes-Genis","year":"2013","journal-title":"J\u00a0Card Fail"},{"key":"10.1053\/j.ajkd.2018.03.025_bib60","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1161\/CIRCHEARTFAILURE.109.873240","article-title":"Interleukin-33 prevents apoptosis and improves survival after experimental myocardial infarction through ST2 signaling","volume":"2","author":"Seki","year":"2009","journal-title":"Circ Heart Fail"},{"key":"10.1053\/j.ajkd.2018.03.025_bib61","doi-asserted-by":"crossref","first-page":"3B","DOI":"10.1016\/j.amjcard.2015.01.034","article-title":"The biology of ST2: the International ST2 Consensus Panel","volume":"115","author":"Pascual-Figal","year":"2015","journal-title":"Am J Cardiol"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S027263861830636X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S027263861830636X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T03:11:58Z","timestamp":1759461118000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S027263861830636X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":61,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["S027263861830636X"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2018.03.025","relation":{},"ISSN":["0272-6386"],"issn-type":[{"value":"0272-6386","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"GDF-15, Galectin 3, Soluble ST2, and Risk of Mortality and Cardiovascular Events in CKD","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2018.03.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 by the National Kidney Foundation, Inc.","name":"copyright","label":"Copyright"}]}}